Continuation of the nuMoM2b Heart Health Study

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in U.S. women at all ages, and large knowledge gaps exist in CVD predictive and preventative strategies for women. The nuMoM2b Heart Health Study (nuMoM2b-HHS) has followed a demographically diverse cohort of women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospectively collected for up to 7 years thereafter. The overarching scientific goal of this study is to define the relationship between adverse pregnancy outcomes (APOs) and CVD to optimize CVD prediction, prevention, and treatment strategies for women. Continued follow-up of this observational cohort, building on a foundation of existing high-quality data, biospecimens, and administrative structures with a robust framework for ancillary study development and implementation, provides a unique opportunity to address knowledge gaps regarding the early mechanisms and trajectory of CVD in women.

NCT Number	NCT05472597
Lead Sponsor	RTI International Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Northwestern University, Ohio State University, Cedars-Sinai Medical Center, Case Western Reserve University, Columbia University, ChristianaCare, Indiana University, University of California, Irvine, University of Utah, University of Pennsylvania, Intermountain Health Care, Inc., University of Michigan, West Virginia University, Old Dominion University, Brown University, Magee-Women's Research Institute, University of Pittsburgh Medical Center
Conditions	Cardiovascular Diseases
Enrollment	4,048 participants
Start Date	2022-11-29
Primary Completion	2027-01 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-01